Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Fructose-1,6-bisphosphatase (FBPase) is a critical regulatory enzyme in gluconeogenesis, catalyzing the hydrolysis of fructose 1,6-bisphosphate to fructose 6-phosphate. This reaction is irreversible and a key control point in glucose production. It is regulated by AMP and fructose 2,6-bisphosphate (inhibition) and ATP (activation). Two main isoforms exist: FBP1 (liver/kidney) and FBP2 (muscle). Deficiency causes hypoglycemia, while overactivity contributes to hyperglycemia in type II diabetes, making it a potential drug target. Increased expression may also play a role in appetite regulation.
Inhibition of fructose-1,6-bisphosphate hydrolysis
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Fructose-1,6-bisphosphatase.